Comparison of Methods of Isolation and Quantification of Cell Free DNA from Plasma of Patients with Breast Cancer.
DOI:
https://doi.org/10.31580/pjmls.v4i4.2435Keywords:
Breast Cancer, Cell-Free DNA, Circulating tumor DNA, Plasma, Isolation, Extraction, QuantificationAbstract
Objective
Cell-free DNA (cfDNA) released in response to necrosis in cancer patients The objective of this study was to compare the efficiency of two commercial and two manual methods for cell-free DNA extraction. as well as to search for a method that is easy to extract the DNA from the plasma and cost-effective.
Methods
Plasma samples seven in number of patients of Breast Cancer was taken. We evaluated DNA quantity and its subsequent amplification obtained by four different cfDNA isolation methods; Modified Phenol Chloroform Isoamyl, Triton Heat Phenol, EpiQUik Circulating Cell-Free DNA isolation Easy kit” (EpiGentek) and “Nucleospin cfDNA kit”. Extracted DNA was quantified using Qubit and quantitative real-time PCR.
Results
Quantity of cf DNA varied between different extractions methods of a total of seven samples analyzed. The highest quantity was found from the samples extracted from the Nucleospin XS kit and the extraction efficiency was significantly higher in a pairwise comparison with the other three methods (p-value <0.0001). The concentration of the cfDNA obtained by all four methods was assessed on a Qubit fluorometer. The concentration was higher for the Nucleospin ?MPC?THP?Epiquik kit The qPCR values were consistently higher for Nucleospin XS as compared to all others. This indicates good amplifiability of Nucleospin XS
Conclusion
We tested four methods of cf DNA extraction. In our hands, Nucleospin XS gave the best yield and amplifiability. It is a quick and cost-effective method and sensitive for quantification of cfDNA on Real-time PCR. Therefore, it is highly recommended for clinical use of plasma as a liquid biopsy.
References
1. Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P. About the possible origin and mechanism of circulating DNA: Apoptosis and active DNA release. Clinica chimica acta. 2001;313(1-2):139-42.
Schwarzenbach H, Pantel K. Circulating DNA as biomarker in breast cancer. Breast Cancer Research. 2015;17(1):1-9.
Kohler C, Barekati Z, Radpour R, Zhong XY. Cell-free DNA in the circulation as a potential cancer biomarker. Anticancer research. 2011;31(8):2623-8.
Aung KL, Board RE, Ellison G, Donald E, Ward T, Clack G, Ranson M, Hughes A, Newman W, Dive C. Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. The HUGO journal. 2010;4(1):11-21.
Lui YY, Woo KS, Wang AY, Yeung CK, Li PK, Chau E, Ruygrok P, Lo YD. Origin of plasma cell-free DNA after solid organ transplantation. Clinical chemistry. 2003;49(3):495-6.
Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, Marass F. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497(7447):108-12.
Kirsch C, Weickmann S, Schmidt B, Fleischhacker M. An improved method for the isolation of free‐circulating plasma DNA and cell‐free DNA from other body fluids. Wiley Online Libr. 2008;1137:135–9.
Ziegler A, Zangemeister-Wittke U, Stahel RA. Circulating DNA: a new diagnostic gold mine?. Cancer treatment reviews. 2002;28(5):255-71.
Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer—a survey. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2007;1775(1):181-232.
Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nature reviews Clinical oncology. 2013;10(8):472-84.
Marzese DM, Hirose H, Hoon DSB. Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. Expert Rev Mol Diagn. 2013;13(8):827–44.
van der Leest P, Boonstra PA, Ter Elst A, van Kempen LC, Tibbesma M, Koopmans J, Miedema A, Tamminga M, Groen HJ, Reyners AK, Schuuring E. Comparison of circulating cell-free DNA extraction methods for downstream analysis in cancer patients. Cancers. 2020;12(5):1222.
Yang HX. Long-term survival of early-stage non–small cell lung cancer patients who underwent robotic procedure: a propensity score-matched study. Chinese journal of cancer. 2016;35(1):1-3.
Sorber L, Zwaenepoel K, Deschoolmeester V, Roeyen G, Lardon F, Rolfo C, Pauwels P. A comparison of cell-free DNA isolation kits: isolation and quantification of cell-free DNA in plasma. The journal of molecular diagnostics. 2017;19(1):162-8.
Hufnagl C, Stöcher M, Moik M, Geisberger R, Greil R. A modified phenol-chloroform extraction method for isolating circulating cell free DNA of tumor patients. Journal of Nucleic Acids Investigation. 2013;4(1):e1-.
Devonshire AS, Whale AS, Gutteridge A, Jones G, Cowen S, Foy CA, et al. Towards standardisation of cell-free DNA measurement in plasma: Controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem. 2014;406(26):6499–512.
Miller FD, Pozniak CD, Walsh GS. Neuronal life and death: an essential role for the p53 family. Cell Death & Differentiation. 2000;7(10):880-8.
Park JL, Kim HJ, Choi BY, Lee HC, Jang HR, Song KS, Noh SM, Kim SY, Han DS, Kim YS. Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients. Oncology letters. 2012;3(4):921-6.
Gang F, Guorong L, An Z, Anne GP, Christian G, Jacques T. Prediction of clear cell renal cell carcinoma by integrity of cell-free DNA in serum. Urology. 2010;75(2):262-5.
Khani M, Pouresmaeili F, Mirfakhraie R. Evaluation of extracted circulating cell free DNA concentration by Standard Nucleospin Plasma XS (NS) kit protocol compared to its modified protocol. Urol Nephrol Open Access. 2017;4(4):00137.
Whale AS, Huggett JF, Cowen S, Speirs V, Shaw J, Ellison S, Foy CA, Scott DJ. Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. Nucleic acids research. 2012;40(11):e82-.
Hayden RT, Gu Z, Ingersoll J, Abdul-Ali D, Shi L, Pounds S, Caliendo AM. Comparison of droplet digital PCR to real-time PCR for quantitative detection of cytomegalovirus. Journal of clinical microbiology. 2013;51(2):540-6.
Xue X, Teare MD, Holen I, Zhu YM, Woll PJ. Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. Clinica chimica acta. 2009;404(2):100-4.
Mauger F, Dulary C, Daviaud C, Deleuze JF, Tost J. Comprehensive evaluation of methods to isolate, quantify, and characterize circulating cell-free DNA from small volumes of plasma. Analytical and bioanalytical chemistry. 2015;407(22):6873-8.
Schmidt B, Weickmann S, Witt C, Fleischhacker M. Improved method for isolating cell-free DNA. Clinical chemistry. 2005;51(8):1561-3.
Yuan H, Zhu ZZ, Lu Y, Liu F, Zhang W, Huang G, Zhu G, Jiang B. A modified extraction method of circulating free DNA for epidermal growth factor receptor mutation analysis. Yonsei medical journal. 2012;53(1):132-7.
